北京大学定量生物学中心

学术报告

题 目： Biodesign for industrial biotechnology

报告人： Prof. Igor Goryanin

Henrik Kacser Chair in Systems Biology, University of Edinburgh, UK Adjunct Professor, Okinawa Institute of Science and Technology, Japan Adjunct Professor, Tianjin Institute of Industrial Biotechnology, China

时 间： 2016年11月07日(周一)13：00-14：00

地 点： 北京大学老化学楼东配楼101报告厅

主持人： 汤超 教授

摘要：

There is a great potential for the use of microbes in the synthesis of bio-based industrial compounds. Systems metabolic engineering for strain redesign is a promising approach to improve the prospects of using microbial hosts for production of high value biofuels or natural products. The successful development of microbial factories is essential to add value to the production of compounds ranging from biofuels to pharmaceuticals. These successes pose a number of challenges including： a lack of well characterized enzymes, poor activity of selected pathway enzymes, low product titers, poor yield and selectivity, metabolic burden and unfavorable cofactor balancing. Some of these challenges could be addressed by advances in computational tools and modelling for systems metabolic engineering, biochemistry, protein engineering, and synthetic and molecular biology. A number of experimental and in silico tools have been produced to address some of these challenges. It is necessary to recognize that experimental and computational breakthroughs remain the key aspects of any progress made so far. It is now clear that experimental and computational breakthroughs go hand-in-hand, and when fully integrated, biodesign could play a significant role in systems metabolic engineering and may serve as a major driver of applied synthetic biology.

报告人简介：

Goryanin is a systems biologist, who holds a Henrik Kacser Chair in Computational Systems Biology at the University of Edinburgh, and leads the Computational Systems Biology and Bioinformatics group, School of Informatics. He heads the Biological Systems Unit at Okinawa Institute Science and Technology, Japan. His research Interests are systems biology and systems medicine including human biochemical network reconstruction, modelling of complex biological systems, microbial fuel cells and other biotechnology and bioinformatics applications. Goryanin graduated (MSc) in 1985 as an applied mathematician from the Computer Science Department, Moscow Engineering Physical Institute (MEPHI), where he was developing numerical methods and algorithms for analysis of stiff differential equations. Prof. Goryanin spent more than twelve years working in the Institute of Biophysics, Russian Academy of Science and obtained his PhD in 1995 at the same Institute. During this time he developed DBSolve, a software for mathematical stimulation and analysis of the cellular metabolism and regulation (Goryanin is an author for DBSolve). From 1989 to 1995 he was also CEO and co-founder of Biobank Inc., Russia. In 1995–1997 Goryanin worked as a Visiting Computer Scientist at the Mathematics & Computer Science Division, Argonne National Laboratories. He joined GlaxoSmithKline (formerly known as GlaxoWellcome) in 1997. Goryanin was working on application of modelling and informatics techniques to the pharmaceutical research and development and drugs manufacturing industry. The whole cell modelling of organisms approach developed by Goryanin has been successfully used to improve drug R&D and manufacturing process in production plants, i.e. designing anti-microbial assays and anti-microbial drug targets identification, rational organism design, rational biomarker design and target prioritisation, reconstructing cellular networks for cancers, metabolic and lipid disorders. In 2005 Goryanin moved to Edinburgh to take the position of a Henrik Kacser Chair in Computational Systems Biology. In 2006 Goryanin developed one of the first Masters courses in Computational Systems Biology in the UK, currently taught at the University of Edinburgh. He co-founded the Centre for Systems Biology at Edinburgh, where he was a co-director (2006–2010), and Edinburgh Centre for Bioinformatics, where he was a director (2005–2010).